Quetiapine, widely recognized under the brand name Seroquel, is a medication approved by the FDA for the treatment of various mental health conditions, including schizophrenia, acute manic episodes linked to bipolar I disorder, and as an adjunct therapy for major depressive disorder. Beyond these approved uses, it is also utilized off-label for conditions such as generalized anxiety disorder. Available in both extended-release (once-daily) and immediate-release (twice-daily) formulations, quetiapine’s versatility necessitates a comprehensive understanding for healthcare providers to effectively guide patient therapy. This article aims to provide an in-depth overview of quetiapine, covering its approved and off-label uses, mechanism of action, administration methods, potential adverse effects, contraindications, monitoring guidelines, and toxicity profiles. This knowledge will empower healthcare professionals to optimize patient care when quetiapine is indicated.
Objectives:
- Detail the FDA-approved and off-label applications of quetiapine in treating various conditions.
- Enumerate and explain the potential adverse effects associated with quetiapine use.
- Clarify the mechanism of action through which quetiapine exerts its therapeutic effects.
- Emphasize the crucial role of interprofessional team communication in managing and mitigating the adverse effects of quetiapine.
Indications for Seroquel Diagnosis and Treatment
Seroquel (quetiapine) holds FDA approval for several key psychiatric conditions. It is a recognized treatment for schizophrenia in both adults and adolescents (13-17 years old), supported by multiple clinical trials. These trials established an effective dosage range of 150 mg to 750 mg daily for adults, with optimal effects often observed around 300 mg to 500 mg. For adolescents with schizophrenia, studies have shown quetiapine to be effective at average doses ranging from 400 mg/day to 800 mg/day.
Alt text: Various dosage strengths of Seroquel (quetiapine) tablets, used in seroquel diagnosis and treatment of mental health conditions.
In the realm of bipolar disorder, Seroquel is indicated for acute manic episodes in adults and children (10-17 years old). For adults, the effective dose range for managing acute mania typically falls between 400 mg/day and 800 mg/day. Quetiapine has also demonstrated efficacy as an adjunctive treatment to mood stabilizers like lithium or divalproex in managing manic episodes. Furthermore, it is effective in treating depressive episodes associated with bipolar I and II disorders in adults, with a generally effective dose of 300 mg/day. Maintenance therapy trials have confirmed its role in sustaining stability in bipolar disorder at dosages of 400 mg/day to 800 mg/day.
Beyond its FDA-approved uses, quetiapine is frequently used off-label. One prominent off-label application is in the treatment of generalized anxiety disorder (GAD). Several randomized controlled trials support its effectiveness as monotherapy for GAD compared to placebo. While research supports other off-label uses, including psychosis in Parkinson’s disease, insomnia, PTSD, and as an adjunct in OCD, borderline personality disorder, and major depressive disorder, more robust clinical trials are often needed to secure FDA approval for these indications. Despite the limited formal approvals for these conditions, quetiapine is commonly prescribed for symptomatic relief of insomnia, agitation, and anxiety in various psychiatric contexts. However, clinicians are advised to exercise caution with long-term off-label use due to the potential for side effects outweighing the benefits in the absence of well-established efficacy data.
Mechanism of Action in Seroquel Diagnosis
Quetiapine’s therapeutic action is multifaceted, primarily involving interactions with various neurotransmitter receptors in the brain. It exhibits a strong affinity for serotonin 5-HT2 receptors, and its antipsychotic effects are largely attributed to its antagonistic activity at these receptors. Additionally, quetiapine acts on dopamine D1 and D2 receptors, functioning as an antagonist at D2 receptors and 5-HT2 receptors.
Alt text: Chemical structure of quetiapine, highlighting its complex molecular composition relevant to seroquel diagnosis and mechanism of action.
The anxiolytic and antidepressant properties of quetiapine, along with its active metabolite norquetiapine, are believed to arise from norepinephrine transporter (NET) inhibition and partial agonist activity at the 5-HT1A receptor, respectively. Blocking D2 receptors in the mesocortical and mesolimbic pathways is crucial for managing both negative and positive symptoms of schizophrenia, as dopamine dysregulation in these pathways is implicated in the disorder. Further research suggests that quetiapine’s antidepressant effects are also mediated by its antagonistic properties at 5-HT2A and 5-HT7 receptors. Norquetiapine, the active metabolite, also interacts with a broad spectrum of receptors, including histamine H1, serotonergic 5-HT1E, 5-HT2A, 5-HT2B, 5-HT7, muscarinic M1, M3, and M5, and α1-adrenergic receptors, contributing to the complex pharmacological profile of quetiapine.
Administration and Dosage for Seroquel
Quetiapine is available in immediate-release (IR) and extended-release (ER) formulations, allowing for flexible dosing regimens. IR quetiapine is typically administered two to three times daily, while ER quetiapine is designed for once-daily dosing. Tablets come in a range of strengths, from 25 mg to 400 mg for IR, and 50 mg to 400 mg for ER formulations. The maximum recommended daily dose for IR quetiapine is 800 mg, usually divided into two or three doses. Quetiapine is rapidly absorbed after oral administration, reaching peak plasma concentrations within 1 to 2 hours, with an elimination half-life of approximately 7 hours.
Dosage Guidelines (Oral Administration):
For Schizophrenia:
- Immediate-Release (IR): Initial dose of 25 mg twice daily, titrated gradually to a target range of 150 to 750 mg daily, divided into two or three doses. Daily increases should be in the range of 50 to 150 mg. Elderly patients should have slower titration, with daily increases of 25 to 50 mg.
- Extended-Release (ER): Start at 300 mg daily, increasing up to 300 mg daily as needed, to a target range of 400 to 800 mg, administered once in the evening. For elderly patients, start at 50 mg daily with 50 mg increments. ER tablets should not be chewed, crushed, or cut.
For Bipolar I Disorder (Manic):
- IR: Starting dose is 50 mg twice daily, increased to 200 mg twice daily by day four, then further increased by up to 200 mg per day as needed, with a maximum dose of 800 mg daily.
For Bipolar I Disorder (Manic/Mixed):
- ER: Begin with 300 mg on day one, then 600 mg on day two, adjusting by 200 mg per day as needed, up to a maximum of 800 mg daily, administered in the evening. Elderly patients should start at 50 mg in the evening with 50 mg daily increments.
For Acute Depressive Bipolar Disorder:
- IR: Initiate at 50 mg at bedtime on day one, increasing to 300 mg at bedtime by day four (100 mg on day two, 200 mg on day three, then 300 mg). Maximum recommended dose is 600 mg daily, although doses above 300 mg rarely show additional benefit. For elderly patients, start at 25 mg at bedtime with daily increases of 25 to 50 mg.
- ER: Starting dose of 50 mg in the evening, titrated to 300 mg in the evening by day four (100 mg on day two, 200 mg on day three, then 300 mg). The maximum daily dose is 300 mg. Elderly patients should start at 50 mg in the evening with 50 mg daily dose increments. ER tablets should not be chewed, crushed, or cut.
As an adjunctive treatment for major depressive disorder, IR quetiapine is used at doses ranging from 50 to 300 mg daily, and ER quetiapine at 150 to 300 mg daily, using similar titration schedules to a maximum of 300 mg daily. For optimal efficacy in most conditions, a dosage range of 300 mg to 800 mg per day is generally considered effective. In some cases, for non-FDA-approved indications, doses up to 1200 mg to 1600 mg per day may be considered under close monitoring, particularly for QT interval prolongation.
Adverse Effects of Seroquel
Like all antipsychotic medications, quetiapine carries a risk of adverse effects. A critical warning associated with quetiapine is an increased risk of death in elderly patients with dementia-related psychosis. Neuroleptic malignant syndrome (NMS), though rare, is another serious consideration due to quetiapine’s D2 receptor blockade. However, quetiapine is considered less likely to cause extrapyramidal symptoms (EPS) compared to many other antipsychotics. It’s important to note that there is an elevated risk of suicidal thoughts and behaviors, particularly in younger patients with major depressive disorder, especially at the initiation of treatment.
Alt text: A patient experiencing dizziness, a common adverse effect associated with seroquel diagnosis and medication use.
Common side effects of quetiapine include somnolence, orthostatic hypotension, and dizziness. Somnolence and dizziness are largely attributed to quetiapine’s antagonism of histamine H1 receptors, while orthostatic hypotension is related to alpha-1 receptor antagonism. Other potential adverse effects include stroke, myocarditis, and coronary heart disease, which have been linked to quetiapine use in some studies.
Contraindications and Precautions for Seroquel Use
Currently, there are no absolute FDA contraindications to quetiapine. However, several precautions are critical to consider before and during its administration. As previously mentioned, quetiapine and other atypical antipsychotics are associated with increased mortality risk in elderly patients with dementia-related psychosis.
Caution is advised when using quetiapine with other drugs that prolong the QT interval, as this combination can increase the risk of torsades de pointes, a life-threatening arrhythmia. These drugs include Class I and Class III antiarrhythmics, other antipsychotics, macrolide antibiotics, fluoroquinolones, pentamidine, levomethadyl acetate, methadone, tricyclic antidepressants, quinine, halofantrine, and albendazole. Precaution is also necessary in patients with pre-existing prolonged QT intervals, a history of cardiac arrhythmia, hypokalemia, or hypomagnesemia.
Metabolic monitoring is crucial; clinicians should consider obtaining baseline metabolic panels before starting quetiapine. Patients with diabetes mellitus should have their glucose levels closely monitored due to the risk of hyperglycemia and hyperosmolar coma. Quetiapine is generally not recommended for breastfeeding women, and its use during pregnancy should be carefully considered, weighing the benefits against potential risks to the fetus.
Monitoring Patients on Seroquel
The therapeutic range for quetiapine is generally considered to be between 100 ng/mL to 1000 ng/mL. Within this range, patients may experience common side effects such as somnolence, dizziness, and orthostatic hypotension. Other common side effects include tachycardia, dyspnea, cough, pharyngitis, rhinitis, nasal congestion, dry mouth, constipation, dyspepsia, abdominal pain, leukopenia, neutropenia, lethargy, hyperlipidemia, hyperglycemia, peripheral edema, sedation, weight gain, and tardive dyskinesia.
Regular monitoring is essential for patients taking quetiapine. This should include metabolic panels with a focus on fasting glucose, cholesterol, and triglyceride levels, as well as blood pressure and weight monitoring. For patients on long-term quetiapine therapy, lens examinations every six months are recommended to monitor for cataract development. Although rare, agranulocytosis is a reported side effect, warranting awareness and potential monitoring of complete blood counts in susceptible individuals.
Toxicity and Overdose Management of Seroquel
Quetiapine overdose can be life-threatening. Toxicity is typically associated with serum or plasma levels exceeding 1500 ng/mL. Management of quetiapine toxicity is primarily supportive. In cases of acute overdose, immediate measures should focus on maintaining a patent airway, ensuring adequate oxygenation, and ventilation. Gastric lavage and activated charcoal administration, along with a laxative, may be considered if performed shortly after ingestion to limit further drug absorption. Quetiapine reaches peak plasma concentrations within 1 to 2 hours post-ingestion.
Alt text: ECG monitoring being performed on a patient, crucial for detecting cardiac arrhythmias in seroquel diagnosis and potential toxicity.
ECG monitoring is recommended to detect potential QT-interval prolongation and arrhythmias like torsades de pointes. Extrapyramidal symptoms can be managed with anticholinergic medications, and hypotension should be treated with intravenous fluids and sympathomimetic agents like A1 agonists. In cases of neuroleptic malignant syndrome, immediate cessation of quetiapine is necessary, followed by supportive management of symptoms.
While no definitive antidote for quetiapine toxicity exists, intravenous lipid emulsion (ILE) has shown promise in case reports for reversing severe toxicity, possibly due to quetiapine’s lipophilic nature. Physostigmine, a muscarinic agonist, has also been reported in case series to successfully reverse significantly altered mental status in quetiapine overdose.
Enhancing Healthcare Team Outcomes in Seroquel Therapy
Given the potential for significant side effects associated with quetiapine, a collaborative, interprofessional healthcare team approach is essential for patient safety and optimal outcomes. Nurses, pharmacists, and clinicians must effectively communicate and collaborate to monitor patients receiving quetiapine therapy. This interprofessional collaboration ensures comprehensive patient care and proactive management of potential adverse events. [Level 5 evidence]
Review Questions
[Link to review questions if available – If link was provided in original article, include it here]
References
[Include all references from the original article, ensuring they are correctly formatted and linked if possible]
1.Garriga M, Solé E, González-Pinto A, Selva-Vera G, Arranz B, Amann BL, Saiz-Ruiz J, Pérez-Blanco J, Vieta E. Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial. Eur Neuropsychopharmacol. 2017 Oct;27(10):959-969. [PubMed: 28882405]
2.Suttajit S, Srisurapanont M, Maneeton N, Maneeton B. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther. 2014;8:827-38. [PMC free article: PMC4077390] [PubMed: 25028535]
3.Lindström L, Lindström E, Nilsson M, Höistad M. Maintenance therapy with second generation antipsychotics for bipolar disorder – A systematic review and meta-analysis. J Affect Disord. 2017 Apr 15;213:138-150. [PubMed: 28222360]
4.Maneeton N, Maneeton B, Woottiluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, Srisurapanont M. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2016;10:259-76. [PMC free article: PMC4716733] [PubMed: 26834458]
5.Villarreal G, Hamner MB, Cañive JM, Robert S, Calais LA, Durklaski V, Zhai Y, Qualls C. Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2016 Dec 01;173(12):1205-1212. [PubMed: 27418378]
6.Yuan M, Sperry L, Malhado-Chang N, Duffy A, Wheelock V, Farias S, O’Connor K, Olichney J, Shahlaie K, Zhang L. Atypical antipsychotic therapy in Parkinson’s disease psychosis: A retrospective study. Brain Behav. 2017 Jun;7(6):e00639. [PMC free article: PMC5474696] [PubMed: 28638698]
7.Nagata T, Nakajima S, Shinagawa S, Plitman E, Nakayama K, Graff-Guerrero A, Mimura M. Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer’s Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study. J Alzheimers Dis. 2017;60(1):263-272. [PubMed: 28800334]
8.Riedel M, Schmitz M, Østergaard PK, Ferrannini L, Franco MA, Alfano V, Vansvik ED. Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: a randomised, double-blind, crossover study (eXtRa). Schizophr Res. 2015 Mar;162(1-3):162-8. [PubMed: 25592805]
9.Weber SR, Wehr AM, Duchemin AM. Prevalence of antipsychotic prescriptions among patients with anxiety disorders treated in inpatient and outpatient psychiatric settings. J Affect Disord. 2016 Feb;191:292-9. [PubMed: 26688499]
10.Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl). 1993;112(2-3):285-92. [PubMed: 7871032]
11.Cross AJ, Widzowski D, Maciag C, Zacco A, Hudzik T, Liu J, Nyberg S, Wood MW. Quetiapine and its metabolite norquetiapine: translation from in vitro pharmacology to in vivo efficacy in rodent models. Br J Pharmacol. 2016 Jan;173(1):155-66. [PMC free article: PMC4813385] [PubMed: 26436896]
12.Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology. 2008 Sep;33(10):2303-12. [PubMed: 18059438]
13.Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):199-204. [PubMed: 18948162]
14.Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care. 2012 Jul 26;16(4):R136. [PMC free article: PMC3580721] [PubMed: 22835221]
15.DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509-22. [PubMed: 11510628]
16.Bergman H, Walker DM, Nikolakopoulou A, Soares-Weiser K, Adams CE. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess. 2017 Aug;21(43):1-218. [PMC free article: PMC5572117] [PubMed: 28812541]
17.Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757-777. [PMC free article: PMC5499790] [PubMed: 28721057]
18.Aronow WS, Shamliyan TA. Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders. Ann Transl Med. 2018 Apr;6(8):147. [PMC free article: PMC5952011] [PubMed: 29862236]
19.Jain V, Patel RK, Kapadia Z, Galiveeti S, Banerji M, Hope L. Drugs and hyperglycemia: A practical guide. Maturitas. 2017 Oct;104:80-83. [PubMed: 28923179]
20.Levine M, Ruha AM. Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management. CNS Drugs. 2012 Jul 01;26(7):601-11. [PubMed: 22668123]
21.Minns AB, Clark RF. Toxicology and overdose of atypical antipsychotics. J Emerg Med. 2012 Nov;43(5):906-13. [PubMed: 22555052]
22.Arslan ED, Demir A, Yilmaz F, Kavalci C, Karakilic E, Çelikel E. Treatment of quetiapine overdose with intravenous lipid emulsion. Keio J Med. 2013;62(2):53-7. [PubMed: 23708294]
23.Bartos M, Knudsen K. Use of intravenous lipid emulsion in the resuscitation of a patient with cardiovascular collapse after a severe overdose of quetiapine. Clin Toxicol (Phila). 2013 Jul;51(6):501-4. [PubMed: 23768031]
24.Cole JB, Stellpflug SJ, Ellsworth H, Harris CR. Reversal of quetiapine-induced altered mental status with physostigmine: a case series. Am J Emerg Med. 2012 Jul;30(6):950-3. [PubMed: 21802878]
Disclosures:
Jasdave Maan, Mona Ershadi, Israr Khan, and Abdolreza Saadabadi declare no relevant financial relationships with ineligible companies.
